Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View Full Press Release Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS Travere Therapeutics to Participate at Upcoming Investor Conferences